Manipulation of indoleamine 2,3 dioxygenase; a novel therapeutic target for treatment of diseases
- 17 June 2009
- journal article
- review article
- Published by Taylor & Francis in Emerging Therapeutic Targets
- Vol. 13 (8), 987-1012
- https://doi.org/10.1517/14728220903018940
Abstract
Background: The discovery of indoleamine 2,3-dioxygenase (IDO) as a modulator for the maintenance of fetomaternal immuno-privileged state has been heralded as a significant step in further defining the role of IDO in immunobiology. IDO is an IFN-inducible, intracellular enzyme that catalyzes the initial and rate-limiting step in the degradation of the essential amino acid, tryptophan. It has been suggested that IDO has the capacity to regulate the immune system via two discrete mechanisms; firstly the deprivation of tryptophan, which is essential for T cell proliferation and via the cytotoxic effects of tryptophan metabolites on TH1 cell survival. Methods: The sources of information used to prepare the paper are published work on Pubmed/Medline. In this review, we examine the therapeutic role of modulating IDO activity a variety of disease states including tumour tolerance, chronic infection, transplant rejection, autoimmunity and asthma. We propose that IDO represents a novel therapeutic target for the treatment of these diseases. We also explore the diverse strategies which are being employed, either to augment or to inhibit IDO activity in order to modify various disease processes. The limitations associated with these strategies are also scrutinized.Keywords
This publication has 102 references indexed in Scilit:
- Therapeutic effect of exosomes from indoleamine 2,3‐dioxygenase–positive dendritic cells in collagen‐induced arthritis and delayed‐type hypersensitivity disease modelsArthritis & Rheumatism, 2009
- Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenaseProceedings of the National Academy of Sciences, 2008
- Structure Based Development of Phenylimidazole-Derived Inhibitors of Indoleamine 2,3-DioxygenaseJournal of Medicinal Chemistry, 2008
- Modulation of invariant natural killer T cell cytokine responses by indoleamine 2,3-dioxygenaseImmunology Letters, 2008
- 3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosisProceedings of the National Academy of Sciences, 2007
- Uveal melanoma expression of indoleamine 2,3-deoxygenase: Establishment of an immune privileged environment by tryptophan depletionExperimental Eye Research, 2007
- Mechanisms of local immunosuppression in cutaneous melanomaBritish Journal of Cancer, 2007
- Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancerBritish Journal of Cancer, 2006
- A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined ImmunodeficiencyNew England Journal of Medicine, 2003
- Heme-Containing OxygenasesChemical Reviews, 1996